Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GLUE NASDAQ:LNTH NASDAQ:PTGX NASDAQ:RYTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLUEMonte Rosa Therapeutics$17.59-0.8%$18.37$4.12▼$25.77$1.50B1.6784,009 shs882,138 shsLNTHLantheus$100.25+4.1%$86.93$47.25▼$103.89$6.27B-0.031.15 million shs1.08 million shsPTGXProtagonist Therapeutics$95.41+2.3%$101.42$49.38▼$107.84$6.00B1.85530,944 shs579,220 shsRYTMRhythm Pharmaceuticals$84.71+0.4%$87.31$60.70▼$122.20$5.78B1.91662,629 shs416,107 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLUEMonte Rosa Therapeutics-9.81%-7.60%-5.64%-4.67%+294.22%LNTHLantheus-0.85%-3.76%+12.63%+23.72%+24.85%PTGXProtagonist Therapeutics-1.82%-6.79%-5.26%-1.73%+85.82%RYTMRhythm Pharmaceuticals-4.01%-6.09%+3.10%-7.31%+32.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLUEMonte Rosa Therapeutics$17.59-0.8%$18.37$4.12▼$25.77$1.50B1.6784,009 shs882,138 shsLNTHLantheus$100.25+4.1%$86.93$47.25▼$103.89$6.27B-0.031.15 million shs1.08 million shsPTGXProtagonist Therapeutics$95.41+2.3%$101.42$49.38▼$107.84$6.00B1.85530,944 shs579,220 shsRYTMRhythm Pharmaceuticals$84.71+0.4%$87.31$60.70▼$122.20$5.78B1.91662,629 shs416,107 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLUEMonte Rosa Therapeutics-9.81%-7.60%-5.64%-4.67%+294.22%LNTHLantheus-0.85%-3.76%+12.63%+23.72%+24.85%PTGXProtagonist Therapeutics-1.82%-6.79%-5.26%-1.73%+85.82%RYTMRhythm Pharmaceuticals-4.01%-6.09%+3.10%-7.31%+32.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGLUEMonte Rosa Therapeutics 2.67Moderate Buy$32.5084.76% UpsideLNTHLantheus 2.73Moderate Buy$101.861.60% UpsidePTGXProtagonist Therapeutics 2.88Moderate Buy$115.2120.76% UpsideRYTMRhythm Pharmaceuticals 2.83Moderate Buy$131.8155.60% UpsideCurrent Analyst Ratings BreakdownLatest GLUE, LNTH, PTGX, and RYTM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026RYTMRhythm Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/27/2026LNTHLantheus MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$100.00 ➝ $115.005/26/2026LNTHLantheus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)5/21/2026PTGXProtagonist Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$135.005/21/2026PTGXProtagonist Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$135.005/15/2026PTGXProtagonist Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)5/11/2026GLUEMonte Rosa Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D)5/11/2026GLUEMonte Rosa Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$30.00 ➝ $31.005/11/2026LNTHLantheus Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$98.00 ➝ $115.005/8/2026LNTHLantheus CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/8/2026LNTHLantheus Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$85.00 ➝ $115.00(Data available from 6/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGLUEMonte Rosa Therapeutics$123.67M12.02N/AN/A$3.58 per share4.91LNTHLantheus$1.54B4.23$6.65 per share15.08$16.43 per share6.10PTGXProtagonist Therapeutics$46.02M133.33N/AN/A$9.83 per share9.71RYTMRhythm Pharmaceuticals$189.76M30.59N/AN/A$2.08 per share40.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGLUEMonte Rosa Therapeutics-$38.63M-$1.48N/AN/AN/A-302.69%-40.99%-25.94%8/6/2026 (Estimated)LNTHLantheus$233.56M$4.1524.1618.67N/A18.05%29.32%15.00%8/5/2026 (Estimated)PTGXProtagonist Therapeutics-$130.15M-$1.81N/AN/AN/A-154.88%-17.76%-16.47%8/5/2026 (Estimated)RYTMRhythm Pharmaceuticals-$196.54M-$3.13N/AN/AN/A-93.33%-203.25%-44.99%8/4/2026 (Estimated)Latest GLUE, LNTH, PTGX, and RYTM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026GLUEMonte Rosa Therapeutics-$0.3882-$0.45-$0.0618-$0.45$10.95 million$4.21 million5/7/2026Q1 2026LNTHLantheus$1.25$1.46+$0.21$1.80$354.48 million$377.33 million5/5/2026Q1 2026PTGXProtagonist Therapeutics-$0.5004$0.05+$0.5504$0.05$11.70 million$56.37 million5/5/2026Q1 2026RYTMRhythm Pharmaceuticals-$0.86-$0.83+$0.03-$0.83$55.78 million$60.11 million3/17/2026Q4 2025GLUEMonte Rosa Therapeutics-$0.45-$0.55-$0.10-$0.55$17.09 million$2.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGLUEMonte Rosa TherapeuticsN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGLUEMonte Rosa TherapeuticsN/A9.549.54LNTHLantheus0.472.832.64PTGXProtagonist TherapeuticsN/A17.7617.76RYTMRhythm PharmaceuticalsN/A4.173.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGLUEMonte Rosa Therapeutics79.96%LNTHLantheus99.06%PTGXProtagonist Therapeutics98.63%RYTMRhythm PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipGLUEMonte Rosa Therapeutics6.40%LNTHLantheus1.70%PTGXProtagonist Therapeutics5.19%RYTMRhythm Pharmaceuticals5.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGLUEMonte Rosa Therapeutics9084.48 million79.07 millionOptionableLNTHLantheus1,19365.11 million64.00 millionOptionablePTGXProtagonist Therapeutics12064.31 million60.97 millionOptionableRYTMRhythm Pharmaceuticals14068.53 million64.49 millionOptionableGLUE, LNTH, PTGX, and RYTM HeadlinesRecent News About These CompaniesRhythm Pharmaceuticals: The Rare Obesity Platform Is Becoming A Commercial EngineJune 3 at 8:40 AM | seekingalpha.comZweig DiMenna Associates LLC Buys New Shares in Rhythm Pharmaceuticals, Inc. $RYTMMay 30, 2026 | marketbeat.comRhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026May 29, 2026 | globenewswire.comRhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical GeneticsMay 28, 2026 | globenewswire.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Average Rating of "Moderate Buy" from AnalystsMay 28, 2026 | americanbankingnews.comRhythm Pharmaceuticals Announces Participation in Upcoming Investor ConferencesMay 26, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM) and Cardiff Oncology (CRDF)May 22, 2026 | theglobeandmail.comRhythm Pharmaceuticals, Inc. (RYTM) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comHC Wainwright Issues Pessimistic Outlook for RYTM EarningsMay 13, 2026 | marketbeat.comComerica Bank Cuts Stake in Rhythm Pharmaceuticals, Inc. $RYTMMay 13, 2026 | marketbeat.comRhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of EndocrinologyMay 12, 2026 | markets.businessinsider.comRhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of EndocrinologyMay 12, 2026 | globenewswire.comRhythm Pharmaceuticals (NASDAQ:RYTM) Upgraded by Wall Street Zen to "Hold" RatingMay 9, 2026 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This YearMay 8, 2026 | finance.yahoo.comRhythm Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 7, 2026 | seekingalpha.comRhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $137.00 at Royal Bank Of CanadaMay 6, 2026 | marketbeat.comWells Fargo & Company Boosts Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $144.00May 6, 2026 | marketbeat.comRhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare ConferenceMay 6, 2026 | globenewswire.comRhythm Pharmaceuticals Weighs Long Term IMCIVREE Data And Growth PotentialMay 5, 2026 | finance.yahoo.comRhythm Pharmaceuticals, Inc. (RYTM) Q1 2026 Earnings Call TranscriptMay 5, 2026 | seekingalpha.comRhythm Pharmaceuticals Q1 Earnings Call HighlightsMay 5, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGLUE, LNTH, PTGX, and RYTM Company DescriptionsMonte Rosa Therapeutics NASDAQ:GLUE$17.59 -0.15 (-0.85%) Closing price 04:00 PM EasternExtended Trading$17.57 -0.02 (-0.14%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.Lantheus NASDAQ:LNTH$100.25 +3.95 (+4.10%) Closing price 04:00 PM EasternExtended Trading$100.18 -0.08 (-0.07%) As of 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Protagonist Therapeutics NASDAQ:PTGX$95.41 +2.18 (+2.34%) Closing price 04:00 PM EasternExtended Trading$95.39 -0.02 (-0.02%) As of 05:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Rhythm Pharmaceuticals NASDAQ:RYTM$84.71 +0.36 (+0.43%) Closing price 04:00 PM EasternExtended Trading$84.00 -0.71 (-0.84%) As of 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coke's $10B India IPO Plan Pops the Top on Hidden Value Palo Alto Networks Accelerates Growth 31% on AI Demand Motorola's $1.5B Bet to Own the Skies Microsoft Build 2026 Is Really Just One Big AI Stress Test FedEx Unboxes Billions in Post-Spinoff Value Slice of the Pie: Why Yum’s Deal Lifts QSR Urban Outfitters Stock Stalls Despite Another Strong Quarter What IBM's $10-Billion Quantum Project Means For Smaller Players Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
